(VIANEWS) – Xylem (XYL), Astrazeneca (AZN), STAAR Surgical Company (STAA) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Xylem (XYL)
37.6% sales growth and 8.9% return on equity
Xylem Inc., together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions for the water and wastewater applications in the United States, Europe, the Asia Pacific, and internationally. It operates through three segments: Water Infrastructure, Applied Water, and Measurement & Control Solutions. The Water Infrastructure segment offers various products, including water, storm water, and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment and rental services under the Flygt, Godwin, Sanitaire, Leopold, Wedeco, and Xylem Vue brand names for the transportation and treatment of water. The Applied Water segment provides pumps, valves, heat exchangers, controls, and dispensing equipment systems under the Goulds Water Technology, Bell & Gossett, A-C Fire Pump, Standard Xchange, Lowara, Jabsco, Xylem Vue, and Flojet brand names for residential and commercial building services, and industrial water applications. The Measurement & Control Solutions segment offers smart meters, networked communication devices, data analytics, test equipment, controls, sensor devices, software and managed services, and critical infrastructure services; and software and services, including cloud-based analytics, remote monitoring and data management, leak detection, condition assessment, asset management, and pressure monitoring solutions, as well as testing equipment. This segment sells its products under the Pure Technologies, Sensus, Smith Blair, WTW, Xylem Vue, and YSI brand names. The company markets and sells its products through a network of direct sales force, resellers, distributors, and value-added solution providers. Xylem Inc. was formerly known as ITT WCO, Inc. and changed its name to Xylem Inc. in May 2011. Xylem Inc. was incorporated in 2011 and is headquartered in Washington, District of Columbia.
Earnings Per Share
As for profitability, Xylem has a trailing twelve months EPS of $2.79.
PE Ratio
Xylem has a trailing twelve months price to earnings ratio of 45.91. Meaning, the purchaser of the share is investing $45.91 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.9%.
Yearly Top and Bottom Value
Xylem’s stock is valued at $128.10 at 19:22 EST, under its 52-week high of $128.16 and way above its 52-week low of $87.59.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Xylem’s EBITDA is 4.38.
Sales Growth
Xylem’s sales growth is 36.4% for the present quarter and 37.6% for the next.
2. Astrazeneca (AZN)
13.7% sales growth and 15.64% return on equity
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Earnings Per Share
As for profitability, Astrazeneca has a trailing twelve months EPS of $1.91.
PE Ratio
Astrazeneca has a trailing twelve months price to earnings ratio of 33.89. Meaning, the purchaser of the share is investing $33.89 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.64%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Astrazeneca’s EBITDA is 4.8.
Sales Growth
Astrazeneca’s sales growth is 13.5% for the present quarter and 13.7% for the next.
3. STAAR Surgical Company (STAA)
13.4% sales growth and 5.57% return on equity
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Earnings Per Share
As for profitability, STAAR Surgical Company has a trailing twelve months EPS of $0.38.
PE Ratio
STAAR Surgical Company has a trailing twelve months price to earnings ratio of 81.18. Meaning, the purchaser of the share is investing $81.18 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.57%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.6%, now sitting on 310.19M for the twelve trailing months.
Sales Growth
STAAR Surgical Company’s sales growth is 18.1% for the ongoing quarter and 13.4% for the next.
Volume
Today’s last reported volume for STAAR Surgical Company is 678408 which is 15.27% below its average volume of 800710.
4. ProLogis (PLD)
12.4% sales growth and 5.62% return on equity
Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. At December 31, 2023, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 1.2 billion square feet (115 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 6,700 customers principally across two major categories: business-to-business and retail/online fulfillment.
Earnings Per Share
As for profitability, ProLogis has a trailing twelve months EPS of $3.28.
PE Ratio
ProLogis has a trailing twelve months price to earnings ratio of 40.73. Meaning, the purchaser of the share is investing $40.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.62%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.7%, now sitting on 8.33B for the twelve trailing months.
Sales Growth
ProLogis’s sales growth is 14% for the current quarter and 12.4% for the next.
5. Huron Consulting Group (HURN)
8.7% sales growth and 13.83% return on equity
Huron Consulting Group Inc., a professional services firm, provides consultancy services in the United States and internationally. It operates through three segments: Healthcare, Education, and Commercial. The Healthcare segment provides advisory services in the areas of financial and operational improvement, care transformation, and revenue cycle managed services; organizational transformation; financial advisory; software products; and digital solutions, spanning technology and analytic-related services to national and regional health systems, academic and community health systems, public, children's and critical access hospitals, physician practices and medical groups, payors, and long-term care or post-acute providers. The Education segment provides research enterprise, and student and alumni lifecycle; digital solutions, spanning technology, and analytic-related services; Huron Research Suite, a software suite designed to facilitate and enhance research administration service delivery and compliance; and organizational transformation services to public and private colleges and universities, research institutes, and other education-related organizations. The Commercial segment delivers digital services and software products, and financial advisory services to financial, energy and utilities, professional and business services, life science, consumer products, and industrials and manufacturing industries, as well as public sector and nonprofit organizations. The company was incorporated in 2002 and is headquartered in Chicago, Illinois.
Earnings Per Share
As for profitability, Huron Consulting Group has a trailing twelve months EPS of $3.89.
PE Ratio
Huron Consulting Group has a trailing twelve months price to earnings ratio of 27.05. Meaning, the purchaser of the share is investing $27.05 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.83%.
Sales Growth
Huron Consulting Group’s sales growth is 8.9% for the present quarter and 8.7% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 0.9% and 10.3%, respectively.
6. CBIZ (CBZ)
8.1% sales growth and 16.08% return on equity
CBIZ, Inc. provides financial, insurance, and advisory services in the United States and Canada. The company operates through three segments: Financial Services, Benefits and Insurance Services, and National Practices. The Financial Services segment offers accounting and tax, government healthcare consulting, financial advisory, valuation, and risk and advisory services. The Benefits and Insurance Services provides group health benefits consulting, payroll, property and casualty, and retirement plan services. The National Practices segment offers managed networking and hardware, and health care consulting services. It primarily serves small and medium-sized businesses, as well as individuals, governmental entities, and not-for-profit enterprises. The company was founded in 1987 and is headquartered in Cleveland, Ohio.
Earnings Per Share
As for profitability, CBIZ has a trailing twelve months EPS of $2.39.
PE Ratio
CBIZ has a trailing twelve months price to earnings ratio of 31.89. Meaning, the purchaser of the share is investing $31.89 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.08%.
Sales Growth
CBIZ’s sales growth is 8% for the present quarter and 8.1% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 4.2% and 37.7%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
CBIZ’s EBITDA is 2.72.
